아시아 태평양 위암 진단 시장 – 2030년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

아시아 태평양 위암 진단 시장 – 2030년까지의 산업 동향 및 예측

  • Healthcare IT
  • Published Report
  • Mar 2023
  • Asia-Pacific
  • 350 Pages
  • 테이블 수: 249
  • 그림 수: 56

Asia Pacific Gastric Cancer Diagnostics Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
2024 –2030
Diagram 시장 규모(기준 연도)
백만 달러
Diagram 시장 규모(예측 연도)
미국 달러 471.25
Diagram 연평균 성장률
%
Diagram주요 시장 플레이어
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>아시아 태평양 위암 진단 시장, 제품 유형(기구, 시약 및 소모품, 서비스), 진단 유형(확인 검사, 위암 선별 검사/신체 검사), 연령대(성인, 소아 및 노인), 질병 유형(장 또는 확산성 선암, 카르시노이드 종양, 위장관 기질 종양 (GIST), 위 림프종 및 기타), 병기(0기, 1기, 2기, 3기), 성별(남성 및 여성), 샘플 유형(혈액, 조직, 소변 및 대변), 최종 사용자(진단 실험실, 병원, 암 연구소, 종양 전문 클리닉 및 기타), 유통 채널(직접 입찰 및 소매 판매) - 업계 동향 및 2030년까지의 예측.

아시아 태평양 위암 진단 시장

아시아 태평양 위암 진단 시장 분석 및 통찰력

아시아 태평양 노령 인구의 증가는 위암 진단 산업의 성장을 주도하고 있습니다. 위장관 종양과 림프종의 유병률도 위암 진단에 대한 수요를 촉진했습니다. 주요 시장 제약은 개발도상국도 혜택을 볼 수 있도록 암 진단 검사와 관련된 높은 가격을 낮춰야 한다는 필요성입니다.

아시아 태평양 위암 진단 시장아시아 태평양 위암 진단 시장

수많은 시장 주체가 혁신을 통해 위암 진단 제품을 제공하며, 이는 위암 진단 시장 성장의 길을 열어주고 있습니다.

Data Bridge Market Research는 아시아 태평양 위암 진단 시장이 2030년까지 4억 7,125만 달러에 도달할 것으로 예상되며, 예측 기간 동안 CAGR은 10.0%라고 분석했습니다. 시약과 소모품은 키트와 시약에 대한 수요가 증가하고 의료비 지출이 증가함에 따라 스마트 의료 기기에 대한 수요가 가속화되어 시장에서 가장 큰 제품 유형 세그먼트를 차지합니다.

보고서 메트릭

세부

예측 기간

2023년부터 2030년까지

기준 연도

2022

역사적 연도

2021 (2015-2020으로 사용자 정의 가능)

양적 단위

매출은 백만 달러, 볼륨은 단위, 가격은 달러로 표시됨

다루는 세그먼트

제품 유형별(기구, 시약 및 소모품, 서비스), 진단 유형별(확증 검사, 위암 검진 검사/신체 검사), 연령대별(성인, 소아 및 노인), 질병 유형별(장 또는 확산성 선암, 카르시노이드 종양, 위장관 기질 종양(GIST), 위 림프종 및 기타), 병기별(0기, 1기, 2기, 3기), 성별별(남성 및 여성), 샘플 유형별(혈액, 조직, 소변 및 대변), 최종 사용자별(진단 실험실, 병원, 암 연구소, 종양학 전문 병원 및 기타), 유통 채널별(직접 입찰 및 소매 판매)

적용 국가

일본, 중국, 호주, 인도, 한국, 싱가포르, 인도네시아, 태국, 말레이시아, 필리핀, 기타 아시아 태평양 지역

시장 참여자 포함

BIOMÉRIEUX, Myriad Genetics, Inc., ACON Laboratories, Inc., Vela Diagnostics, Abbott, AdvaCare Pharma, MiRXES, Fujirebio (An H.U. Group company), Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Endofotonics Pte Ltd, Biohit Oyj, DiaSorin S.p.A, Paragon Genomics, Inc., and QIAGEN among others

Market Definition

Stomach cancer is a type of cancer that starts in the stomach and spreads throughout the body. The stomach is a muscular pouch that lies immediately below the ribs in the upper part of the abdomen. The stomach takes in and holds the food we eat before breaking it down and digesting it. Stomach cancer, commonly referred to as gastric cancer, can occur in any section of the stomach. Stomach cancers develop in the major section of the stomach in most parts of the world (stomach body). Various diagnostic tests used for the diagnosis of cancer include prescreening tests, biopsy, biomarkers, imaging tests, PET/CT scans, and ultrasound among others.

Cancer is caused by uncontrolled, abnormal cell proliferation that has the ability to spread and invade other sections of the body. Changes in the gene cause a single cell or a few cells to expand and replicate, which is when cancer begins. This could lead to the growth of a tumor, which is an abnormal mass of tissue. The creation of cancer cells in the stomach lining is known as gastric cancer or stomach cancer. Diet and stomach disorders are both risk factors for gastric cancer.

Asia-Pacific Gastric Cancer Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

 Drivers

  • Increase in incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma

According to a report published in Clinical Medicine, gastric cancer is the fifth most common cancer and the fourth leading cause of cancer death worldwide in 2020. In 2020, an estimated 1.1 million cases (720,000 males and 370,000 females) of gastric cancer were diagnosed worldwide. Gastric cancer is responsible for about 1 in every 12 oncological fatalities. Every year, about a million new instances of stomach cancer are diagnosed around the world.

It is projected that the incidence of gastric cancer will rise, due to to aging and increasing population, lifestyle, and socioeconomic change. Striking variations in race, sociocultural norms, behaviors, and dietary trends are reflected in the burden and distribution of cancer in different regions across the globe.

Thus, the rising incidence of cancers across the globe is expected to accelerate the demand for gastric cancer diagnostics. Thus the increased incidence rates of gastrointestinal tumors, lymphoma, and adenocarcinoma are expected to drive the growth of the Asia-Pacific gastric cancer diagnostics market.

  • Rise in alcohol consumption and surge in smoking

Epidemiological, clinical, and laboratory evidence point to a behavioral relationship between cigarette smoking and alcohol consumption. The combined use of cigarettes and alcohol poses health concerns in addition to those posed by smoking alone and so represents a severe public health issue that warrants further investigation.

A chemical chain reaction occurs every time a smoker inhales a lit cigarette, producing dozens of hazardous chemicals. Cigarette smoke contains substances that are inhaled through the lips, through the tongue and mouth, down the throat, and into the lungs, producing inflammation and exposing those bodily parts to cancer-causing chemicals.

Thus, the rise in alcohol consumption and surge in smoking is expected to drive the Asia-Pacific gastric cancer market growth.

Opportunity

  • Rise in adoption of automated systems

Cancer is a system and network illness. This indicates that in a cancer cell, certain network-related genes stop working properly. Complex interactions in such gene networks should be addressed in cancer treatment. Artificial intelligence (AI) algorithms, in particular, have been rapidly evolving, which is reflected in oncology's progress.

Machine learning and neural networks are becoming increasingly significant in precision oncology and system medicine. The combination of imaging data with clinical and molecular data opens up a world of possibilities. Radiogenomics, for instance, is a new field focused on multidimensional data processing. It can also benefit from AI advancements.

Thus, the increased adoption of automated systems acts as an opportunity for the growth of this market.

Restraint/Challenge

  • Lack of sufficient financial support from health insurance policies

To achieve their objectives, health systems require financial resources. Human resources, hospital care, and medications are the most expensive aspects of most healthcare systems. In most tropical countries, health care is funded through a combination of government, private (mainly out-of-pocket) spending, and international help.

Healthcare finance remains a key concern for low- and lower-middle-income countries. Many upper-middle-income countries in Latin America, Africa, and Asia have been able to establish health finance arrangements that cover large segments of their populations. These measures enable access to health care while also protecting individuals from catastrophic debt incurred as a result of that access. Finance, on the other hand, is a major obstacle to health care delivery in low-income countries (the bulk of which are in Sub-Saharan Africa).

Thus, the lack of sufficient financial support from health insurance policies acts as a restraint to market's growth.

Recent Developments

  • 2022년 10월, 제너럴 일렉트릭 컴퍼니는 케임브리지 대학 병원, 소피아 제네틱스, 그리고 그 전에는 옵텔럼과 같은 여러 연구 기관과 협력하여 인공지능과 협력하여 영상 데이터를 사용했습니다. 이를 통해 여러 암의 진단 시간을 단축하고 환자에게 개인화된 치료를 제공하는 데 도움이 될 것입니다. 이를 통해 회사는 암 진단 분야에서 시야를 넓힐 수 있었습니다.
  • 2020년 3월 Thermo Fisher Scientific Inc.는 네덜란드에 본사를 둔 분자 진단 및 헬스케어 회사인 QIAGEN을 인수한다고 발표했습니다. 이 회사의 인수는 시장에서 제품 포트폴리오를 늘려 향후 매출 증가로 이어질 것입니다.

아시아 태평양 위암 진단 시장 범위

아시아 태평양 위암 진단 시장은 제품 유형, 진단 유형, 연령대, 질병 유형, 단계, 성별, 샘플, 최종 사용자 및 유통 채널을 기준으로 9개의 주요 세그먼트로 세분화됩니다. 세그먼트 간 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.

제품 유형

  • 악기
  • 시약 및 소모품
  • 서비스

제품 유형을 기준으로 시장은 기기, 시약 및 소모품, 서비스로 구분됩니다.

진단 유형

  • 확인 테스트
  • 위암 검진 검사/신체 검사

진단 유형을 기준으로 시장은 위암 검진 검사/신체 검사와 확인 검사로 구분됩니다.

연령대

  • 성인
  • 소아과
  • 노년의학

연령대를 기준으로 시장은 성인, 소아, 노년층으로 구분됩니다.

유형

  • 장 또는 확산성 선암
  • 카르시노이드 종양
  • 위장관 기질 종양 (GIST)
  • 위 림프종
  • 기타

시장은 유형을 기준으로 장 또는 확산성 선암, 카르시노이드 종양, 위장관 기질 종양(GIST), 위 림프종 등으로 구분됩니다.

단계

  • 0단계
  • 1단계
  • 2단계
  • 3단계

시장은 단계를 기준으로 0단계, 1단계, 2단계, 3단계로 구분됩니다.

성별

  • 남성
  • 여성

성별을 기준으로 시장은 남성과 여성으로 구분됩니다.

샘플 유형

  • 조직
  • 오줌
  • 발판

샘플 유형을 기준으로 시장은 혈액, 조직, 소변, 대변으로 구분됩니다.

최종 사용자

  • 진단 실험실
  • 병원
  • 암 연구소
  • 종양학 전문 클리닉
  • 기타

최종 사용자를 기준으로 시장은 진단 실험실, 병원, 암 연구소, 종양학 전문 클리닉 등으로 구분됩니다.

유통 채널

  • 직접 입찰
  • 소매 판매

유통 채널을 기준으로 시장은 직접 입찰과 소매 판매로 구분됩니다.

아시아 태평양 위암 진단 시장 지역 분석/통찰력

아시아 태평양 위암 진단 시장은 제품 유형, 진단 유형, 연령대, 질병 유형, 단계, 성별, 샘플, 최종 사용자 및 유통 채널을 기준으로 9개의 주요 세그먼트로 구분됩니다. 

이 시장 보고서에서 다루는 국가는 일본, 중국, 호주, 인도, 한국, 싱가포르, 인도네시아, 태국, 말레이시아, 필리핀, 그리고 나머지 아시아 태평양 지역입니다.

한국은 의료기기 연구개발 및 생명과학 연구에 대한 투자가 증가함에 따라 아시아 태평양 위암 진단 시장을 장악할 것으로 예상됩니다.

보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 국내 시장의 개별 시장 영향 요인과 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 아시아 태평양 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 위암 진단 시장 점유율 분석

아시아 태평양 위암 진단 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 승인, 제품 폭과 범위, 응용 프로그램 우세, 제품 유형 수명선 곡선입니다. 위에 제공된 데이터 포인트는 아시아 태평양 위암 진단 시장에 대한 회사의 초점과만 관련이 있습니다.

시장에서 활동하는 주요 기업으로는 BIOMÉRIEUX, Myriad Genetics, Inc., ACON Laboratories, Inc., Vela Diagnostics, Abbott, AdvaCare Pharma, MiRXES, Fujirebio(HU 그룹 계열사), Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Endofotonics Pte Ltd, Biohit Oyj, DiaSorin SpA, Paragon Genomics, Inc., QIAGEN 등이 있습니다.

 


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PESTEL'S MODEL

4.2 PORTER'S 5 FORCES

4.3 EPIDEMIOLOGY

4.4 BRAND ANALYSIS

4.5 ROLE OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML): ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET

4.6 INDUSTRY INSIGHTS:

5 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, REGULATORY

5.1 ASIA-PACIFIC

5.1.1 REGULATORY SCENARIO IN AUSTRALIA-

5.1.2 REGULATORY SCENARIO IN JAPAN

5.1.3 REGULATORY SCENARIO IN CHINA

5.1.4 REGULATORY SCENARIO IN SINGAPORE-

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMOURS, LYMPHOMA, AND ADENOCARCINOMA

6.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING

6.1.3 INCREASE IN THE GERIATRIC POPULATION

6.1.4 RECENT ADVANCEMENTS IN GASTRIC CANCER DIAGNOSTICS PRODUCTS

6.2 RESTRAINTS

6.2.1 HIGH COST OF GASTRIC CANCER DIAGNOSTIC TEST

6.2.2 LACK OF SUFFICIENT FINANCIAL SUPPORT FROM HEALTH INSURANCE POLICIES

6.3 OPPORTUNITIES

6.3.1 RISE IN THE ADOPTION OF AUTOMATED SYSTEMS

6.3.2 INCREASED RESEARCH AND DEVELOPMENT ON CANCER DIAGNOSTICS PRODUCTS

6.3.3 STRATEGIC INITIATIVES BY EMERGING PLAYERS

6.4 CHALLENGES

6.4.1 STRINGENT REGULATIONS AND POLICIES FOR APPROVING THE COMPLICATED NATURE OF RADIATION DEVICES

6.4.2 LIMITATIONS OF RADIATION TESTS

7 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 REAGENTS & CONSUMABLES

7.2.1 KITS

7.2.1.1 DNA POLYMERASE KITS

7.2.1.2 PCR KITS

7.2.1.3 NUCLEIC ACID ISOLATION KITS

7.2.1.4 OTHERS

7.2.2 REAGENTS

7.2.2.1 ASSAYS

7.2.2.2 BUFFERS

7.2.2.3 PRIMERS

7.2.2.4 OTHERS

7.3 INSTRUMENTS

7.4 SERVICES

8 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE

8.1 OVERVIEW

8.2 CONFIRMATORY TEST

8.2.1 IMAGING TESTS

8.2.1.1 PET SCAN/CT SCAN

8.2.1.2 CT SCAN

8.2.1.3 ULTRASOUND

8.2.1.4 MRI

8.2.1.5 X-RAY

8.2.2 BIOMARKER

8.2.2.1 DNA BIOMARKER

8.2.2.2 RNA BIOMARKER

8.2.2.3 PROTEIN BIOMARKER

8.2.3 BIOPSY

8.3 GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM

9 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP

9.1 OVERVIEW

9.2 GERIATRICS

9.3 ADULT

9.4 PEDIATRIC

10 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE

10.1 OVERVIEW

10.2 INTESTINAL OR DIFFUSE ADENOCARCINOMA

10.3 CARCINOID TUMOR

10.4 GASTROINTESTINAL STROMAL TUMOR

10.5 GASTRIC LYMPHOMA

10.6 OTHERS

11 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE

11.1 OVERVIEW

11.2 STAGE I

11.2.1 STAGE IA

11.2.2 STAGE IB

11.3 STAGE II

11.3.1 STAGE IIA

11.3.2 STAGE IIB

11.4 STAGE III

11.4.1 STAGE IIIA

11.4.2 STAGE IIIB

11.4.3 STAGE IIIC

11.5 STAGE 0

12 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER

12.1 OVERVIEW

12.2 MALE

12.3 FEMALE

13 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE

13.1 OVERVIEW

13.2 STOOL

13.3 TISSUE

13.4 BLOOD

13.5 URINE

14 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 DIAGNOSTIC LABORATORIES

14.4 CANCER RESEARCH INSTITUTES

14.5 ONCOLOGY SPECIALTY CLINICS

14.6 OTHERS

15 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDERS

15.3 RETAIL SALES

16 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION

16.1 ASIA-PACIFIC

16.1.1 SOUTH KOREA

16.1.2 JAPAN

16.1.3 CHINA

16.1.4 AUSTRALIA

16.1.5 SINGAPORE

16.1.6 INDIA

16.1.7 THAILAND

16.1.8 MALAYSIA

16.1.9 INDONESIA

16.1.10 PHILIPPINES

16.1.11 REST OF ASIA-PACIFIC

17 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 F. HOFFMANN-LA ROCHE LTD

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 GENERAL ELECTRIC

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENT

19.3 ABBOTT

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 QIAGEN

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENT

19.5 MYRIAD GENETICS, INC.

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.6 ACON LABORATORIES, INC.

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 ADVACARE PHARMA

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 AGILENT TECHNOLOGIES, INC.

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENTS

19.9 BIOMÉRIEUX

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENT

19.1 BIOCEPT, INC.

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 BIOHIT OYJ

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENT

19.12 DIASORIN S.P.A

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENT

19.13 ENDOFOTONICS PTE LTD

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENT

19.14 FOUNDATION MEDICINE, INC.

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENTS

19.15 FUJIREBIO (AN H.U. GROUP COMPANY)

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENT

19.16 MIRXES PTE LTD.

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

19.17 PARAGON GENOMICS, INC.

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENTS

19.18 TECO DIAGNOSTICS

19.18.1 COMPANY SNAPSHOT

19.18.2 PRODUCT PORTFOLIO

19.18.3 RECENT DEVELOPMENT

19.19 THERMO FISHER SCIENTIFIC INC.

19.19.1 COMPANY SNAPSHOT

19.19.2 REVENUE ANALYSIS

19.19.3 PRODUCT PORTFOLIO

19.19.4 RECENT DEVELOPMENTS

19.2 VELA DIAGNOSTICS

19.20.1 COMPANY SNAPSHOT

19.20.2 PRODUCT PORTFOLIO

19.20.3 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

표 목록

TABLE 1 APPROVED COMPANION DIAGNOSTIC DEVICE

TABLE 2 THE BELOW-MENTIONED LIST SHOWS THE COST OF PET SCAN FOR CANCER DIAGNOSIS IN DIFFERENT REGIONS ACROSS THE GLOBE-

TABLE 3 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 4 ASIA PACIFIC REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 ASIA PACIFIC REAGENT AND CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 6 ASIA PACIFIC KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 7 ASIA PACIFIC REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 8 ASIA PACIFIC INSTRUMENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 ASIA PACIFIC SERVICES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 11 ASIA PACIFIC CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 ASIA PACIFIC CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 13 ASIA PACIFIC IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 14 ASIA PACIFIC BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 15 ASIA PACIFIC GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 17 ASIA PACIFIC GERIATRICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 ASIA PACIFIC ADULT IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 ASIA PACIFIC PEDIATRIC IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 21 ASIA PACIFIC INTESTINAL OR DIFFUSE ADENOCARCINOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 ASIA PACIFIC CARCINOID TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 ASIA PACIFIC GASTROINTESTINAL STROMAL TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 ASIA PACIFIC GASTRIC LYMPHOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 ASIA PACIFIC OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 27 ASIA PACIFIC STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 ASIA PACIFIC STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 29 ASIA PACIFIC STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 ASIA PACIFIC STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 31 ASIA PACIFIC STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 ASIA PACIFIC STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 33 ASIA PACIFIC STAGE 0 IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 34 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 35 ASIA PACIFIC MALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 36 ASIA PACIFIC FEMALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 38 ASIA PACIFIC STOOL IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 ASIA PACIFIC TISSUE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 ASIA PACIFIC BLOOD IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 41 ASIA PACIFIC URINE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 43 ASIA PACIFIC HOSPITALS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 ASIA PACIFIC DIAGNOSTIC LABORATORIES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 45 ASIA PACIFIC CANCER RESEARCH INSTITUTES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 ASIA PACIFIC ONCOLOGY SPECIALTY CLINICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 47 ASIA PACIFIC OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 48 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 49 ASIA PACIFIC DIRECT TENDERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 ASIA PACIFIC RETAIL SALES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 51 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 52 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 53 ASIA-PACIFIC REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 54 ASIA-PACIFIC KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 55 ASIA-PACIFIC REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 56 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 57 ASIA-PACIFIC CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 58 ASIA-PACIFIC BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 59 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 60 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 61 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 62 ASIA-PACIFIC STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 63 ASIA-PACIFIC STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 64 ASIA-PACIFIC STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 65 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 66 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 67 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 68 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 69 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 70 SOUTH KOREA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 71 SOUTH KOREA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 72 SOUTH KOREA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 73 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 74 SOUTH KOREA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 75 SOUTH KOREA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 76 SOUTH KOREA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 77 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 78 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 79 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 80 SOUTH KOREA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 81 SOUTH KOREA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 82 SOUTH KOREA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 83 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 84 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 85 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 86 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 87 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 88 JAPAN REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 89 JAPAN KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 90 JAPAN REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 91 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 92 JAPAN CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 93 JAPAN IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 94 JAPAN BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 95 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 96 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 97 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 98 JAPAN STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 99 JAPAN STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 100 JAPAN STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 101 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 102 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 103 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 104 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 105 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 106 CHINA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 107 CHINA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 108 CHINA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 109 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 110 CHINA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 111 CHINA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 112 CHINA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 113 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 114 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 115 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 116 CHINA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 117 CHINA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 118 CHINA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 119 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 120 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 121 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 122 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 123 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 124 AUSTRALIA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 125 AUSTRALIA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 126 AUSTRALIA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 127 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 128 AUSTRALIA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 129 AUSTRALIA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 130 AUSTRALIA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 131 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 132 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 133 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 134 AUSTRALIA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 135 AUSTRALIA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 136 AUSTRALIA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 137 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 138 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 139 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 140 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 141 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 142 SINGAPORE REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 143 SINGAPORE KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 144 SINGAPORE REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 145 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 146 SINGAPORE CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 147 SINGAPORE IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 148 SINGAPORE BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 149 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 150 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 151 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 152 SINGAPORE STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 153 SINGAPORE STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 154 SINGAPORE STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 155 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 156 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 157 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 158 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 159 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 160 INDIA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 161 INDIA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 162 INDIA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 163 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 164 INDIA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 165 INDIA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 166 INDIA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 167 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 168 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 169 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 170 INDIA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 171 INDIA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 172 INDIA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 173 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 174 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 175 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 176 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 177 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 178 THAILAND REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 179 THAILAND KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 180 THAILAND REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 181 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 182 THAILAND CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 183 THAILAND IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 184 THAILAND BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 185 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 186 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 187 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 188 THAILAND STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 189 THAILAND STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 190 THAILAND STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 191 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 192 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 193 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 194 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 195 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 196 MALAYSIA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 197 MALAYSIA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 198 MALAYSIA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 199 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 200 MALAYSIA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 201 MALAYSIA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 202 MALAYSIA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 203 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 204 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 205 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 206 MALAYSIA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 207 MALAYSIA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 208 MALAYSIA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 209 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 210 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 211 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 212 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 213 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 214 INDONESIA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 215 INDONESIA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 216 INDONESIA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 217 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 218 INDONESIA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 219 INDONESIA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 220 INDONESIA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 221 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 222 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 223 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 224 INDONESIA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 225 INDONESIA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 226 INDONESIA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 227 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 228 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 229 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 230 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 231 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 232 PHILIPPINES REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 233 PHILIPPINES KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 234 PHILIPPINES REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 235 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 236 PHILIPPINES CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 237 PHILIPPINES IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 238 PHILIPPINES BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 239 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 240 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 241 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 242 PHILIPPINES STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 243 PHILIPPINES STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 244 PHILIPPINES STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 245 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 246 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 247 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 248 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 249 REST OF ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

그림 목록

FIGURE 1 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: ASIA PACIFIC VS. REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: MULTIVARIATE MODELLING

FIGURE 7 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: MARKET END COVERAGE GRID

FIGURE 11 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 12 INCREASE IN THE INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA, AND ADENOCARCINOMA IS EXPECTED TO DRIVE THE ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 13 REAGENTS AND CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET IN 2023 & 2030

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES, OF THE ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET

FIGURE 15 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022

FIGURE 16 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)

FIGURE 17 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)

FIGURE 18 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 19 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, 2022

FIGURE 20 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, 2023-2030 (USD MILLION)

FIGURE 21 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, CAGR (2023-2030)

FIGURE 22 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, LIFELINE CURVE

FIGURE 23 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022

FIGURE 24 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)

FIGURE 25 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)

FIGURE 26 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 27 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, 2022

FIGURE 28 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, 2023-2030 (USD MILLION)

FIGURE 29 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, CAGR (2023-2030)

FIGURE 30 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 31 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, 2022

FIGURE 32 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, 2023-2030 (USD MILLION)

FIGURE 33 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, CAGR (2023-2030)

FIGURE 34 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, LIFELINE CURVE

FIGURE 35 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, 2022

FIGURE 36 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION)

FIGURE 37 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030)

FIGURE 38 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE

FIGURE 39 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2022

FIGURE 40 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2023-2030 (USD MILLION)

FIGURE 41 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, CAGR (2023-2030)

FIGURE 42 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, LIFELINE CURVE

FIGURE 43 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, 2022

FIGURE 44 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 45 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 46 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 47 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 48 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 49 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 50 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 51 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 52 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 53 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 54 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 55 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)

FIGURE 56 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The Asia-Pacific Gastric Cancer Diagnostics Market is projected to grow at a CAGR of 10.0% during the forecast period by 2030.
The future market value of the Asia-Pacific Gastric Cancer Diagnostics Market is expected to reach USD 471.25 million by 2030.
The major players in the Asia-Pacific Gastric Cancer Diagnostics Market are BIOMÉRIEUX, Myriad Genetics, Inc., Vela Diagnostics, Abbott, Fujirebio (An H.U. Group company), Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., etc.
The countries covered in the Asia-Pacific Gastric Cancer Diagnostics Market are Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, rest of Asia-Pacific.